Studying clinical of efficiency α-adrenoblockator tamsulozinum at men at of the chronic abacterial prostatitis or chronic pelvic pain syndrome

##plugins.themes.bootstrap3.article.sidebar##

PDF (Русский)
Published: Jun 30, 2017
DOI: https://doi.org/10.30841/2307-5090.2(61).2017.116732
Keywords:
chronic abacterial prostatitis or chronic pelvic pain syndrome, α-adrenoblockator, Tamsin Forte,

##plugins.themes.bootstrap3.article.main##

І. І. Горпинченко
ГУ «Институт урологии НАМН Украины», г. Киев, Ukraine
Ю. М. Гурженко
ГУ «Институт урологии НАМН Украины», г. Киев, Ukraine
В. В. Спиридоненко
ГУ «Институт урологии НАМН Украины», г. Киев, Ukraine
В. В. Козлов
Национальный медицинский университет имени А.А.Богомольца, г. Киев, Ukraine

Abstract

The objective was to evaluate the efficacy of therapy for chronic abacterial prostatitis / chronic pelvic pain syndrome (HAP / CPPS) with Tamsin Forte.
Patients and methods. In the dynamics, 34 patients were examined and treated for HAP / CPPS. For monotherapy, Tamsin Forte (tamsulosin) was used, which refers to highly selective α1-adrenoceptor blockers. The age of the examined patients was from 24 to 42 years. The duration of the disease is from 2 to 4 years. All patients underwent a standard urological examination.
Results. The use of monotherapy with Tamsin Forte provided a quick clinical effect. Painful sensations were eliminated at the end of a three-month course of treatment in 32 (94.1%) of 34 subjects, dysuric phenomena were stopped in 31 (91.2%). In 7 (87.5%) of 8 patients, improvement of erectile function was noted, premature ejaculation was stopped in 9 (81.8%) of 11 patients. After treatment with Tamsin Forte, the maximum speed of urination was significantly increased.
Conclusion. The drug Tamsin Forte is quite effective when used as monotherapy in patients with HAP accompanied by CPPS, as assessed by the doctor (94.2%), and according to the patient's assessment (91.2%). The results obtained make it possible to recommend Tamsin Forte for use in andrological practice.

##plugins.themes.bootstrap3.article.details##

How to Cite
Горпинченко, І. І., Гурженко, Ю. М., Спиридоненко, В. В., & Козлов, В. В. (2017). Studying clinical of efficiency α-adrenoblockator tamsulozinum at men at of the chronic abacterial prostatitis or chronic pelvic pain syndrome. Health of Man, (2(61), 112–116. https://doi.org/10.30841/2307-5090.2(61).2017.116732
Issue
No. 2(61) (2017)
Section
Urology
Copyright (c) 2020 І. І. Горпинченко, Ю. М. Гурженко, В. В. Спиридоненко, В. В. Козлов

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Authors retain the copyright and grant the journal the first publication of original scientific articles under the Creative Commons Attribution 4.0 International License, which allows others to distribute work with acknowledgment of authorship and first publication in this journal.

Author Biographies

І. І. Горпинченко, ГУ «Институт урологии НАМН Украины», г. Киев

I.I. Gorpinchenko

Ю. М. Гурженко, ГУ «Институт урологии НАМН Украины», г. Киев

Yu.M. Gurzhenko

В. В. Спиридоненко, ГУ «Институт урологии НАМН Украины», г. Киев

V.V. Spiridonenko

В. В. Козлов, Национальный медицинский университет имени А.А.Богомольца, г. Киев

V.V. Kozlov

References

Barbalis G.A., Nikifororidis G., Liatsikos E.N. Alpha-blockers for the treatment of chronic prostatitis in combinations with antibiotics / J. Urol. – 1998. – Vol. 159. – P. 993–887.

Bjerclund Johansen T.E., Gruneberg R.N., Guibert J. et. al. The Role of Antibiotics in the Treatment of Chronic Prostatitis: A Consensus Statement. Eur. Urol 998; 34: 457–466.

C.R. Chapple Selective α1A-adrenoceptor antagonists in Benign Prostatic Hyperplasia: rationale and clluinical experience. Eur Urol 1996; 29: 129–44.

Caropreso D, Moon T.D. Current Urology Reports 2000, I: 148–154.

Chappee CR, Carter P, Christmas TJ, et. al. A three-month double-blind study of doxazosin as treatment for benign prostatic obstruction. Br J Urol 1994; 74:50–6.

De la Rosette J.J.M.C., Hubregste M.R., Meuleman E.J.H. et. al. Diagnosis and treatment of 409 patients with prostatitis syndromes. Urology 1993; (41):301–307.

De la Rossette J.J.M.C.H., Karthaus H. F. M., van Kerrebroeck P.E.V.A. et al. Research in ‘prostatic syndromes’: the use of alfusosin (a new alpha-1 receptor blocking agent) in patients mainly presenting with micturition complains of an irritative nature and confirmed urodynamic abnormalities / Eur. Urol. – 1992. – Vol. 22. – P. 222–227.

Dominique G.J., Human L.G., Hellstrom W.J.G. Hidden microorganisms in «abacterial» prostatitis/prostatodynia. J. Urol 1997; 157 ( 4): 243A.

Drach G.W., Meares E.M., Fair W.R., Stamey T.A. Classification of benign diseases associated with prostatic pain: Prostatitis or pros-tatodynia //J. Urology. – 1978. – Vol. 120. – P. 266.

Webster G.D., Lockhart J.L., Older R.A. The evaluation of bladderneck dysfunction. J. Urol. 1980, vol. 123, p. 196.

Gillenwater JY, Conn RL, Chryslant SG, et al. Doxazosin for the treatment of benign prostatic hyperplasia in the patients with mild to moderate essential hypertension. J Urol 154:110–15.

Lepor H: Medical management of benign prostatic hyperplasia. Urology 1993; 42:483–401.

Lepor H: Role of long-acting selective alpha 1 blocker in the treatment of benign prostate hyperplasia. Urol Clin North Am 1990; 17:651–659.

Lowe F.C. Safety assessment of terazosin in the treatment of patient with symptomatic benign prostatic hyperpiesia: a combined analysis // Urology, 44(1): 46–51, 1994.

Mehik A., Alas P., Nickel J.C. et al Alfuzosin treatment for chronic prostatitis/chronic pelvic pain syndrome: a prospective, randomized, double-blind, placebo-controlled, pilot study / Urology. – 2003. – Vol. 62. – P. 425–429.

Neal D.E., Moon T.D. Use of terasosin in prostatodynia and validation of symptom score questionnaire / Urology. – 1994. – Vol. 43. – P. 460–465.

Nickel J.C, Sorensson R. Transurethral microwave thermotherapy of nonbacterial prostatitis and prostatodynia: initial experience //Urology, 1994. – Vol. 44. – P. 458–460.

Nickel J. С Prostatitis: Myths and realities //Urology. – 1998. – Vol. 51. – P. 362–366.

Osborn D.E., George N.J.R., Rao Р./ et al. Prostatodynia: physiological characteristics and rationale management with muscle relaxants / Br. J. Urol. – 1987. – Vol. 53. – P. 621–623.

Roehborn CG, Oesterling JE, Lloyd K, et. al. Hytrin community assessement trial. J Urol 1995; 153: 272A.

Stamey T.A. Pathogenesis and treatment of Urinary Tract Infections. Baltimore, Williams and Wilckins; 1980.342–429.

Theodoroy C., Becopoulos T. Prostatitis. Prostate cancer and Prostatic Diseases 1999; 2: 234–240.

Weidner W., Schiefer H.G, Krauss H. et. al. Chronic prostatitis: A through search for etiologically involved microorganisms in 1461 patients. Infection 1991; 19 (3): 119–125.

Дьяков В.В., Говоров А.В. Опыт длительного применения тамсулозина (омник) у больных хроническим простатитом /Урология. – 2002. – No 5. – С. 1–4.

Молочков В.А., Ильин И.И. Хронический уретрогенный простатит. – М., 1998.

Пушкарь Д.Ю., Коско Д.В., Лоран О.Б. и др. Опыт применения финастерида и теразозина у больных с доброкачественной гиперплазией простаты // Урол. и нефрол. – 1995. – No 4. – С. 32–35.

Руководство по андрологии / Под ред. О.Л. Тиктинского. – Л., 1990.

Руководство по урологии / Под ред. Н.А. Лопаткина. – В 3-х томах. – М., 2006.

Пасєчніков С.П. Бухалов Ю.В. Обґрунтування вибору α1-адреноблокатора для купірування гострої затримки сечі. Институт урологии АМН Украины // Здоровье Мужчины. – 2004. – 3 (10). – С. 158–160.

Сивков А.В., Ощепков В.Н., Егоров А.А. Применение α1-адреноблокаторов у больных хроническим простатитом / Consiliummedicum. – 2002. – Т. 4. – С. 385–390.

Юнда И.Ф. Простатиты. – К., 1987.